Skip to content


Semprex-d (acrivastine) is a small molecule pharmaceutical. Acrivastine was first approved as Semprex-d on 1994-03-25. It is used to treat allergic rhinitis perennial and urticaria in the USA.
Trade Name Semprex-d
Common Name Acrivastine
Indication allergic rhinitis perennial, urticaria
Drug Class Antihistaminics (histamine-H1 receptor antagonists)
Get full access now